mAbxience and OncoPrecision announced on November 18, 2026, an investment, development, and manufacturing agreement for ONC001, OncoPrecision's lead antibody-drug conjugate (ADC) candidate.¹ Under the agreement, mAbxience will handle the development program for the antibody portion of ONC001, from cell line development through process and analytical development, and will manufacture good manufacturing practice (GMP)-grade material to support a planned phase 1 trial.¹
Key facts
- Candidate: ONC001 (OncoPrecision)
- Class: First-in-class CD64-targeting antibody-drug conjugate
- Mechanism: Eliminates leukemic monocytes and tumor-associated macrophages
- Lead indications: Monocytic AML and chronic myelomonocytic leukemia
- Partner: mAbxience, a wholly owned company of Fresenius SE & Co. KGaA
- Scope: Cell line development through process and analytical development; GMP supply
- Investment: Strategic equity stake in OncoPrecision; terms confidential
- Governance: mAbxience CEO Jurgen Van Broeck joins OncoPrecision's board as an observer
- Stage: Preclinical, advancing toward a planned phase 1 trial
- First disclosure: Oral presentation at the 2025 ASH Annual Meeting
“By bringing together our capabilities and long-term commitment, we aim to accelerate ONC001's path to the clinic while creating sustainable value for both companies,” said José Ramón Millán, global portfolio, contract development and manufacturing organization (CDMO) and partnering director at mAbxience, in a company press release.¹
What is ONC001?
ONC001 is a CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages, with lead indications in monocytic acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), both aggressive blood cancers with few effective options and a median survival measured in months, according to the companies.¹ The candidate was first publicly disclosed in an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting and is moving toward first-in-human studies.¹
OncoPrecision, headquartered in New York City, develops precision therapies for hard-to-treat cancers by combining patient-derived biology with artificial intelligence.¹ mAbxience is a wholly owned company of Fresenius SE & Co. KGaA.¹
What are the terms?
mAbxience will contribute scientific expertise, industrial capabilities, and its Smart CoGs approach, supporting the program through manufacture of the first GMP batch for clinical use.¹ The company has also made a strategic investment in OncoPrecision, and Jurgen Van Broeck, chief executive officer of mAbxience, will join OncoPrecision's board of directors as an observer.¹ Financial terms of the investment were not disclosed.¹
“We're thrilled to partner with mAbxience to accelerate ONC001's path to the clinic through their world-class manufacturing capabilities and regulatory expertise,” said Tarek Ali Zaki, cofounder and CEO, OncoPrecision, in the release.¹
How does this deal fit broader ADC manufacturing activity?
The agreement lands amid sustained investment in ADC manufacturing capacity. Lonza said in October 2026 that it would convert existing mid-scale bioconjugation suites at its Visp, Switzerland, site to a standardized single-use platform with 500-L capacity, scheduled for completion in 2027, and add a large-scale facility with 3 multiproduct suites at scales of up to 3000 L, operational from 2028.² That announcement followed a June 2026 expansion of payload-linker capacity at the same site.³